 Source: Daniel Patrick Martin Shutterstock.com MindMed NASDAQ: MNMD stock is on the move Wednesday following positive data from a Phase II clinical trial of MM-120. MM-120 is an LSD treatment in development for patients suffering from anxiety disorders. 